A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 4
- 主要终点
- Phase II dose of MM-151 alone and in combination with irinotecan based either on the maximum tolerated dose (MTD) or maximum dose of 18 mg/kg in patients with advanced solid malignancies.
研究概览
简要总结
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
详细描述
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design exploring weekly, bi-weekly, and tri-weekly dosing schedules. Successive MM-151 monotherapy cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified, and subsequently in combination with irinotecan. The study consists of three parts as follows: MM-151 monotherapy dose escalation (Part 1); MM-151 monotherapy expansion cohort in cetuximab-refractory colorectal cancer (Part 2); MM-151 + irinotecan dose escalation (Part 3). It is expected that approximately 4 study sites will participate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed advanced malignant solid tumor that has recurred or progressed following standard therapy, or that has not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
- •Patients must be > 18 years of age
- •Patients of their legal representatives must be able to understand and sign an informed consent form
- •Patients must have evaluable or measurable tumor(s)
- •Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy
- •Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-151 (an effective form of contraception is an oral contraceptive or a double barrier method)
排除标准
- •Patients for whom potentially curative antineoplastic therapy is available
- •Patients who are pregnant or lactating
- •Patients with an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)
- •Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic); patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial
研究组 & 干预措施
MM-151 Dose Escalation
MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
干预措施: MM-151 (Drug)
MM-151 Expansion in KRAS wild type colorectal cancer
MM-151 given weekly
干预措施: MM-151 (Drug)
MM-151 + irinotecan
MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
干预措施: MM-151 + irinotecan (Drug)
结局指标
主要结局
Phase II dose of MM-151 alone and in combination with irinotecan based either on the maximum tolerated dose (MTD) or maximum dose of 18 mg/kg in patients with advanced solid malignancies.
时间窗: Two years
次要结局
- Number of dose limiting toxicities (DLTs) within a cohort(2 years)
- Adverse event profile of MM-151 alone and in combination with irinotecan(2 years)
- Objective response to MM-151 alone and in combination with irinotecan based on RECIST(2 years)